SMARCA4 and rhabdoid tumor: For example, Leruste et al. reported complete responses in mice with rhabdoid tumors receiving anti-PD1, and Jelinic et al. published durable responses in four patients with SCCOHT treated with anti-PD1 monotherapy, most of whom had deleterious mutations of SMARCA4 [13,101].